Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine

M K Hunjan; C Roberts; S Karim; J Hague

doi:10.1111/ced.14878

Pityriasis rubra pilaris-like eruption following administration of the BNT163b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine

Clin Exp Dermatol. 2022 Jan;47(1):188-190. doi: 10.1111/ced.14878. Epub 2021 Sep 24.

Authors

M K Hunjan¹, C Roberts², S Karim², J Hague¹

Affiliations

¹ Department of Dermatology, Solihull Hospital, University Hospitals Birmingham Foundation NHS Trust, Birmingham, UK.
² Department of Histopathology, Solihull Hospital, University Hospitals Birmingham Foundation NHS Trust, Birmingham, UK.

Abstract

We describe a case of a pityriasis rubra pilaris (PRP)-like eruption occurring following administration of the Pfizer-Biontech mRNA COVID-19 vaccine, with worsening of the condition following the second dose. To our knowledge, this is the first reported case of a PRP-like eruption as a cutaneous adverse event of the Pfizer-Biontech mRNA COVID-19 vaccine.

Publication types

Case Reports
Letter

MeSH terms

BNT162 Vaccine / adverse effects*
COVID-19 / prevention & control*
Drug Eruptions / etiology*
Drug Eruptions / pathology
Humans
Male
Middle Aged
Pityriasis Rubra Pilaris / chemically induced*
Pityriasis Rubra Pilaris / pathology
SARS-CoV-2

Substances

BNT162 Vaccine